BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25657337)

  • 1. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
    Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
    Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
    van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for cytochrome b5 in the In vivo disposition of anticancer and cytochrome P450 probe drugs in mice.
    Henderson CJ; McLaughlin LA; Finn RD; Ronseaux S; Kapelyukh Y; Wolf CR
    Drug Metab Dispos; 2014 Jan; 42(1):70-7. PubMed ID: 24115751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
    Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T
    Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity.
    Pearce RE; McIntyre CJ; Madan A; Sanzgiri U; Draper AJ; Bullock PL; Cook DC; Burton LA; Latham J; Nevins C; Parkinson A
    Arch Biochem Biophys; 1996 Jul; 331(2):145-69. PubMed ID: 8660694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
    Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
    Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
    Yamazaki H; Nakamura M; Komatsu T; Ohyama K; Hatanaka N; Asahi S; Shimada N; Guengerich FP; Shimada T; Nakajima M; Yokoi T
    Protein Expr Purif; 2002 Apr; 24(3):329-37. PubMed ID: 11922748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of hepatic cytochrome b
    Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice.
    Felmlee MA; Lon HK; Gonzalez FJ; Yu AM
    Drug Metab Dispos; 2008 Feb; 36(2):435-41. PubMed ID: 18048490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5.
    Inui H; Maeda A; Ohkawa H
    Biochemistry; 2007 Sep; 46(35):10213-21. PubMed ID: 17691855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of human cytochrome b5 on CYP3A4 activity and stability in vivo.
    Voice MW; Zhang Y; Wolf CR; Burchell B; Friedberg T
    Arch Biochem Biophys; 1999 Jun; 366(1):116-24. PubMed ID: 10334871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
    Han SY; Zhao HY; Zhou N; Zhou F; Li PP
    J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.
    Hasegawa M; Tahara H; Inoue R; Kakuni M; Tateno C; Ushiki J
    Drug Metab Dispos; 2012 Mar; 40(3):474-80. PubMed ID: 22126990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.
    Natsui K; Mizuno Y; Tani N; Yabuki M; Komuro S
    Eur J Drug Metab Pharmacokinet; 2007; 32(4):233-40. PubMed ID: 18348473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
    Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
    Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system.
    Henderson CJ; McLaughlin LA; Wolf CR
    Mol Pharmacol; 2013 Jun; 83(6):1209-17. PubMed ID: 23530090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.
    Corchero J; Granvil CP; Akiyama TE; Hayhurst GP; Pimprale S; Feigenbaum L; Idle JR; Gonzalez FJ
    Mol Pharmacol; 2001 Dec; 60(6):1260-7. PubMed ID: 11723233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
    Hutchinson MR; Menelaou A; Foster DJ; Coller JK; Somogyi AA
    Br J Clin Pharmacol; 2004 Mar; 57(3):287-97. PubMed ID: 14998425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities.
    Nakajima M; Tane K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
    J Pharm Sci; 2002 Apr; 91(4):952-63. PubMed ID: 11948533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.